2 weeks Ago By [email protected] (MENAFN)
( MENAFN - GetNews) DelveInsight's “Pulmonary Hypertension associated with Interstitial Lung disease market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Pulmonary Hypertension associated with Interstitial Lung Disease, historical and forecasted epidemiology, as well as the Pulmonary Hypertension associated with Interstitial Lung Disease market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The Pulmonary Hypertension associated with Interstitial Lung Disease Market is an evolving segment of the global healthcare landscape, driven by the increasing prevalence of the disorder and the continuous development of innovative treatment options. The Pulmonary Hypertension associated with Interstitial Lung Disease market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.
Discover Key Insights into the Pulmonary Hypertension associated with Interstitial Lung Disease Market with DelveInsight's In-Depth Report @ Pulmonary Hypertension associated with Interstitial Lung Disease Market Size Key Takeaways from the Pulmonary Hypertension associated with Interstitial Lung Disease Market Report Stay ahead in the Pulmonary Hypertension associated with Interstitial Lung Disease Therapeutics Market with DelveInsight's Strategic Report @ Pulmonary Hypertension associated with Interstitial Lung Disease Market Outlook Pulmonary Hypertension associated with Interstitial Lung Disease Epidemiology Segmentation in the 7MM Download the report to understand which factors are driving Pulmonary Hypertension associated with Interstitial Lung Disease epidemiology trends @ Pulmonary Hypertension associated with Interstitial Lung Disease Prevalence Pulmonary Hypertension associated with Interstitial Lung Disease Marketed Drugs TYVASO (treprostinil) Inhalation Solution and TYVASO DPI (treprostinil) Inhalation Powder are both prostacyclin mimetics indicated for the treatment of PH-ILD [WHO Group 3]. TYVASO or TYVASO DPI can improve the ability to exercise. In December 2020, the FDA and in March 2024, the EMA granted ODD for treprostinil to treat IPF.
Currently, the drug is in its late developmental phases for IPF. Pulmonary Hypertension associated with Interstitial Lung Disease Emerging Drugs Treprostinil palmitil is a long-acting pulmonary vasodilator prodrug of treprostinil (TRE). It offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
INOpulse drug-device combination therapy under the developmental pipeline of Bellerophon Therapeutics for the treatment of patients with PH-ILD. The device is designed to be portable for ambulatory patients daily inside or outside their homes. INOpulse delivery system is programmed to adjust automatically based on breathing patterns and delivers a constant and appropriate dose independent of the patient's activity.
Get In-Depth Knowledge on Pulmonary Hypertension associated with Interstitial Lung Disease Market Trends and Forecasts with DelveInsight @ Pulmonary Hypertension associated with Interstitial Lung Disease Treatment Market Pulmonary Hypertension associated with Interstitial Lung Disease Market Outlook There is no standard approach to assessing patients' risk of PH. Currently, two formulations of inhaled treprostinil have obtained approval from the US FDA in April 2023 and May 2024 for TYVASO (inhalation solution) and TYVASO DPI (inhalation powder), respectively. The underlying lung disease is optimally treated with supplemental long-term oxygen therapy, diuretics, anticoagulants, and pulmonary rehabilitation.
PH-specific therapy like prostanoids (FLOLAN, treprostinil, iloprost), endothelin receptor antagonists (bosentan, ambrisentan), and phosphodiesterase inhibitors (sildenafil) are used off-label to manage blood pressure. Pulmonary Hypertension associated with Interstitial Lung Disease Market Insights The appearance of increased pulmonary pressures is uniformly a harbinger of poor outcomes, and so is the case in PH-ILD. Advances in therapeutic options have led to an urgency to look for PH in ILD patients.
In the usual care of ILD patients, specific symptoms, physical exam results, and laboratory and imaging findings can point to additional testing, such asechocardiography. However, further studies are needed to overcome several unmet needs on the therapeutic and diagnostic front Unlock Strategic Insights with DelveInsight's Comprehensive Pulmonary Hypertension associated with Interstitial Lung Disease Market Report @ Pulmonary Hypertension associated with Interstitial Lung Disease Market Drivers and Barriers Scope of the Pulmonary Hypertension associated with Interstitial Lung Disease Market Report Table of Content 1: Key Insights 2: Report Introduction 3: Pulmonary Hypertension Associated with Interstitial Lung Disease Market Overview at a Glance 4: Epidemiology and Market Methodology 5: Executive Summary 6: Key Events 7: Disease Background and Overview 8: Epidemiology and Patient Population of PH-ILD 9: Patient Journey 10: Marketed drugs 11: Emerging Drugs 12. Key Cross Competition 13: Unmet Needs 14: SWOT Analysis 15: Key Opinion Leaders' Views 16: Reimbursement and Market Access 17: Appendix 18: DelveInsight Capabilities 19: Disclaimer 20: About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions.
With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. MENAFN06112024003238003268ID1108859144 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind.
We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above..
